Cardiol Therapeutics Expands MAVERIC Trial to Seven Clinical Centers
Cardiol Therapeutics announced the continued expansion of its pivotal Phase III MAVERIC trial in the U.S., with the planned activation of up to seven additional clinical centers. Patient enrollment in MAVERIC surpassed the 50% threshold in early January and has now reached 75%. Target recruitment is anticipated by the end of Q2, with the potential to extend into Q3 to accommodate patient enrollment from additional clinical sites. MAVERIC is a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx for the prevention of disease recurrence in patients with recurrent pericarditis. The study is designed to enroll approximately 110 patients. MAVERIC was designed with input from the FDA, with alignment on trial design achieved at an end-of-Phase II meeting in April 2025. The first patient was randomized at Northwestern University in April 2025. MAVERIC builds on the clinical evidence established in the Phase II MAvERIC study, which demonstrated that CardiolRx produced rapid and sustained reductions in pericarditis pain and inflammation, along with a substantial decrease in recurrent episodes per year.
Trade with 70% Backtested Accuracy
Analyst Views on CRDL
About CRDL
About the author
Cardiol Therapeutics Advances Heart Disease Treatment with CardiolRx™
- Clinical Study Results: Cardiol Therapeutics' Phase II study results indicate that CardiolRx™ significantly reduces pericarditis pain and inflammation in patients with a high baseline disease burden, supporting its further development in the Phase III MAVERIC trial.
- Safety and Tolerability: The study demonstrates that CardiolRx™ has a favorable safety and tolerability profile, significantly reducing the number of pericarditis episodes per year, highlighting its potential as a non-immunosuppressive therapy to meet urgent patient needs.
- Trial Progress: The MAVERIC trial has surpassed 75% enrollment, establishing a solid foundation for the clinical application of CardiolRx™, which is expected to provide more effective treatment options for heart disease patients.
- Independent Validation: The upcoming publication in JAHA provides independent validation of the Phase II study results, further emphasizing the significance of CardiolRx™ in heart disease treatment and its potential to transform existing therapeutic approaches.
Cardiol Expands MAVERIC Trial Centers in U.S.
- Trial Expansion: Cardiol Therapeutics announced the expansion of its pivotal Phase III MAVERIC trial in the U.S. with plans to activate up to seven additional clinical centers, reflecting strong interest in its therapeutic approach and aiming for target recruitment by Q2 2026.
- Patient Recruitment Progress: Enrollment in the MAVERIC trial has surpassed 75%, indicating the company's potential in heart disease treatment, particularly in recurrent pericarditis, which could significantly enhance patient quality of life.
- Clinical Data Support: The MAVERIC trial builds on the Phase II MAvERIC study, which demonstrated that CardiolRx™ rapidly and sustainably reduces pericarditis pain and inflammation, supporting its potential as a non-immunosuppressive oral therapy.
- FDA Designation: CardiolRx™ has received Orphan Drug Designation from the U.S. FDA, further strengthening its market competitiveness in heart disease treatment and expected to provide robust data support for future drug approval applications.
Cardiol Therapeutics Expands MAVERIC Trial with New Clinical Centers
- Patient Recruitment Progress: The MAVERIC trial has surpassed 75% patient enrollment, up from over 50% in early January, with target recruitment expected by the end of Q2 2026, potentially extending into Q3 to accommodate additional clinical sites, thereby accelerating clinical advancements in heart disease treatment.
- Clinical Center Expansion: The planned activation of up to seven additional clinical centers in the U.S. reflects strong interest from leading medical institutions in the MAVERIC trial, which not only enhances the credibility of the research but may also provide richer clinical data to support CardiolRx™'s New Drug Application with the FDA.
- Trial Design and FDA Alignment: The MAVERIC trial has been designed in alignment with the FDA, ensuring scientific rigor and effectiveness, aiming to enroll approximately 110 patients to further validate CardiolRx™'s efficacy in preventing recurrent pericarditis, which holds significant clinical implications.
- Clinical Data Foundation: MAVERIC builds on positive Phase II data, demonstrating that CardiolRx™ can rapidly and sustainably reduce pericarditis pain and inflammation while significantly decreasing recurrence rates, providing strong clinical support for its application in heart disease treatment.
Cardiol Therapeutics (CRDL) Raises $13.5M Through Bought-Deal Private Placement at $1.30/Unit
- Funding Size: Cardiol Therapeutics has entered into a bought-deal agreement with Canaccord Genuity to issue 10.38 million units at $1.30 each, successfully raising $13.5 million, thereby strengthening its financial position for future growth.
- Over-Allotment Option: The underwriter has the option to purchase an additional 10% of the units, potentially increasing proceeds by $1.35 million, providing the company with further funding flexibility.
- Unit Composition: Each unit consists of one Class A common share and one-half of a common share purchase warrant, which can be exercised at $1.75 per share for 24 months post-issuance, enhancing potential returns for investors.
- Use of Proceeds: The proceeds from this financing will be used to advance research and clinical development programs, as well as for working capital and general corporate purposes, reflecting the company's strategic planning for future growth.
MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading
MongoDB's Strong Performance: MongoDB Inc. shares surged 22.8% in pre-market trading after reporting third-quarter revenue of $628.31 million, exceeding analyst expectations, and raising its FY26 guidance.
Other Notable Gainers: Taoping Inc. saw a 64.5% increase after announcing an acquisition, while Fitell Corp. rose 37.6% following a repurchase program announcement.
Significant Losers: Janux Therapeutics Inc. experienced a 39.3% drop in pre-market trading after releasing updated interim data, while American Bitcoin Corp. fell 17% after a previous decline.
Market Overview: The article highlights various stocks moving in pre-market trading, showcasing both significant gainers and losers, reflecting market volatility.
HC Wainwright & Co. Affirms Buy Rating for Cardiol Therapeutics, Keeps $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders succeed in the markets.
Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from timely alerts and insights.
Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.
Cardiol Therapeutics Advances Heart Disease Treatment with CardiolRx™
- Clinical Study Results: Cardiol Therapeutics' Phase II study results indicate that CardiolRx™ significantly reduces pericarditis pain and inflammation in patients with a high baseline disease burden, supporting its further development in the Phase III MAVERIC trial.
- Safety and Tolerability: The study demonstrates that CardiolRx™ has a favorable safety and tolerability profile, significantly reducing the number of pericarditis episodes per year, highlighting its potential as a non-immunosuppressive therapy to meet urgent patient needs.
- Trial Progress: The MAVERIC trial has surpassed 75% enrollment, establishing a solid foundation for the clinical application of CardiolRx™, which is expected to provide more effective treatment options for heart disease patients.
- Independent Validation: The upcoming publication in JAHA provides independent validation of the Phase II study results, further emphasizing the significance of CardiolRx™ in heart disease treatment and its potential to transform existing therapeutic approaches.
Cardiol Expands MAVERIC Trial Centers in U.S.
- Trial Expansion: Cardiol Therapeutics announced the expansion of its pivotal Phase III MAVERIC trial in the U.S. with plans to activate up to seven additional clinical centers, reflecting strong interest in its therapeutic approach and aiming for target recruitment by Q2 2026.
- Patient Recruitment Progress: Enrollment in the MAVERIC trial has surpassed 75%, indicating the company's potential in heart disease treatment, particularly in recurrent pericarditis, which could significantly enhance patient quality of life.
- Clinical Data Support: The MAVERIC trial builds on the Phase II MAvERIC study, which demonstrated that CardiolRx™ rapidly and sustainably reduces pericarditis pain and inflammation, supporting its potential as a non-immunosuppressive oral therapy.
- FDA Designation: CardiolRx™ has received Orphan Drug Designation from the U.S. FDA, further strengthening its market competitiveness in heart disease treatment and expected to provide robust data support for future drug approval applications.
Cardiol Therapeutics Expands MAVERIC Trial with New Clinical Centers
- Patient Recruitment Progress: The MAVERIC trial has surpassed 75% patient enrollment, up from over 50% in early January, with target recruitment expected by the end of Q2 2026, potentially extending into Q3 to accommodate additional clinical sites, thereby accelerating clinical advancements in heart disease treatment.
- Clinical Center Expansion: The planned activation of up to seven additional clinical centers in the U.S. reflects strong interest from leading medical institutions in the MAVERIC trial, which not only enhances the credibility of the research but may also provide richer clinical data to support CardiolRx™'s New Drug Application with the FDA.
- Trial Design and FDA Alignment: The MAVERIC trial has been designed in alignment with the FDA, ensuring scientific rigor and effectiveness, aiming to enroll approximately 110 patients to further validate CardiolRx™'s efficacy in preventing recurrent pericarditis, which holds significant clinical implications.
- Clinical Data Foundation: MAVERIC builds on positive Phase II data, demonstrating that CardiolRx™ can rapidly and sustainably reduce pericarditis pain and inflammation while significantly decreasing recurrence rates, providing strong clinical support for its application in heart disease treatment.
Cardiol Therapeutics (CRDL) Raises $13.5M Through Bought-Deal Private Placement at $1.30/Unit
- Funding Size: Cardiol Therapeutics has entered into a bought-deal agreement with Canaccord Genuity to issue 10.38 million units at $1.30 each, successfully raising $13.5 million, thereby strengthening its financial position for future growth.
- Over-Allotment Option: The underwriter has the option to purchase an additional 10% of the units, potentially increasing proceeds by $1.35 million, providing the company with further funding flexibility.
- Unit Composition: Each unit consists of one Class A common share and one-half of a common share purchase warrant, which can be exercised at $1.75 per share for 24 months post-issuance, enhancing potential returns for investors.
- Use of Proceeds: The proceeds from this financing will be used to advance research and clinical development programs, as well as for working capital and general corporate purposes, reflecting the company's strategic planning for future growth.
MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading
MongoDB's Strong Performance: MongoDB Inc. shares surged 22.8% in pre-market trading after reporting third-quarter revenue of $628.31 million, exceeding analyst expectations, and raising its FY26 guidance.
Other Notable Gainers: Taoping Inc. saw a 64.5% increase after announcing an acquisition, while Fitell Corp. rose 37.6% following a repurchase program announcement.
Significant Losers: Janux Therapeutics Inc. experienced a 39.3% drop in pre-market trading after releasing updated interim data, while American Bitcoin Corp. fell 17% after a previous decline.
Market Overview: The article highlights various stocks moving in pre-market trading, showcasing both significant gainers and losers, reflecting market volatility.
HC Wainwright & Co. Affirms Buy Rating for Cardiol Therapeutics, Keeps $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders succeed in the markets.
Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from timely alerts and insights.
Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.
